Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1473 entries
Sorted by: Best Match Show Resources per page
Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Oncotarget

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N.
PMID: 29545925
Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20.

BACKGROUND: Interferon-free treatment can achieve higher sustained virological response (SVR) rates, even in patients in whom hepatitis C virus (HCV) could not be eradicated in the interferon treatment era. Immune restoration in the liver is occasionally associated with HCV...

Cite
Kanda T, Yasui S, Nakamura M, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9(14):11631-11637doi: 10.18632/oncotarget.24391.
Kanda, T., Yasui, S., Nakamura, M., Nakamoto, S., Takahashi, K., Wu, S., Sasaki, R., Haga, Y., Ogasawara, S., Saito, T., Kobayashi, K., Kiyono, S., Ooka, Y., Suzuki, E., Chiba, T., Maruyama, H., Imazeki, F., Moriyama, M., & Kato, N. (2018). Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 9(14), 11631-11637. https://doi.org/10.18632/oncotarget.24391
Kanda, Tatsuo, et al. "Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis." Oncotarget vol. 9,14 (2018): 11631-11637. doi: https://doi.org/10.18632/oncotarget.24391
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20. PMID: 29545925; PMCID: PMC5837765.
Copy Download .nbib Format: NLM
PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS.

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology

Yasui M, Hattori Y, Uemura K, Ishida H, Teranishi JI, Yumura Y, Miyoshi Y, Kondo K, Uemura H.
PMID: 29070738
Nihon Hinyokika Gakkai Zasshi. 2016;107(4):245-250. doi: 10.5980/jpnjurol.107.245.

(Introduction) A pheochromocytoma diagnosed during pregnancy is rare, and also its fetal and maternal mortality is high if undiagnosed. We report two cases with successful pregnancy outcome with pheochromocytoma. (Case 1) A 31-years-old previously healthy woman presented at 19...

Cite
Yasui M, Hattori Y, Uemura K, et al. PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS. Nihon Hinyokika Gakkai Zasshi. 2016;107(4):245-250doi: 10.5980/jpnjurol.107.245.
Yasui, M., Hattori, Y., Uemura, K., Ishida, H., Teranishi, J. I., Yumura, Y., Miyoshi, Y., Kondo, K., & Uemura, H. (2016). PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 107(4), 245-250. https://doi.org/10.5980/jpnjurol.107.245
Yasui, Masato, et al. "PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS." Nihon Hinyokika Gakkai zasshi. The japanese journal of urology vol. 107,4 (2016): 245-250. doi: https://doi.org/10.5980/jpnjurol.107.245
Yasui M, Hattori Y, Uemura K, Ishida H, Teranishi JI, Yumura Y, Miyoshi Y, Kondo K, Uemura H. PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS. Nihon Hinyokika Gakkai Zasshi. 2016;107(4):245-250. doi: 10.5980/jpnjurol.107.245. Japanese. PMID: 29070738.
Copy Download .nbib Format: NLM
Rhodium-Catalyzed C-O Bond Alkynylation of Aryl Carbamates with Propargyl Alcohols.

Organic letters

Yasui K, Chatani N, Tobisu M.
PMID: 29578720
Org Lett. 2018 Apr 06;20(7):2108-2111. doi: 10.1021/acs.orglett.8b00674. Epub 2018 Mar 26.

The rhodium-catalyzed alkynylation of aryl carbamates with propargyl alcohols is described. This methodology can provide aryl acetylenes from aryl carbamates via C-O bond activation. The use of propargyl alcohols as alkynylating agents allows the use of a variety of...

Cite
Yasui K, Chatani N, Tobisu M. Rhodium-Catalyzed C-O Bond Alkynylation of Aryl Carbamates with Propargyl Alcohols. Org Lett. 2018;20(7):2108-2111doi: 10.1021/acs.orglett.8b00674.
Yasui, K., Chatani, N., & Tobisu, M. (2018). Rhodium-Catalyzed C-O Bond Alkynylation of Aryl Carbamates with Propargyl Alcohols. Organic letters, 20(7), 2108-2111. https://doi.org/10.1021/acs.orglett.8b00674
Yasui, Kosuke, et al. "Rhodium-Catalyzed C-O Bond Alkynylation of Aryl Carbamates with Propargyl Alcohols." Organic letters vol. 20,7 (2018): 2108-2111. doi: https://doi.org/10.1021/acs.orglett.8b00674
Yasui K, Chatani N, Tobisu M. Rhodium-Catalyzed C-O Bond Alkynylation of Aryl Carbamates with Propargyl Alcohols. Org Lett. 2018 Apr 06;20(7):2108-2111. doi: 10.1021/acs.orglett.8b00674. Epub 2018 Mar 26. PMID: 29578720.
Copy Download .nbib Format: NLM
Operative Treatment for Osteochondral Lesions of the Talus: Biologics and Scaffold-Based Therapy.

Cartilage

Yasui Y, Wollstein A, Murawski CD, Kennedy JG.
PMID: 27994719
Cartilage. 2017 Jan;8(1):42-49. doi: 10.1177/1947603516644298. Epub 2016 May 09.

OBJECTIVE: Numerous basic science articles have published evidence supporting the use of biologic augmentation in the treatment of osteochondral lesions of the talus (OLT). However, a comprehensive evaluation of the clinical outcomes of those treatment modalities in OLT has...

Cite
Yasui Y, Wollstein A, Murawski CD, et al. Operative Treatment for Osteochondral Lesions of the Talus: Biologics and Scaffold-Based Therapy. Cartilage. 2016;8(1):42-49doi: 10.1177/1947603516644298.
Yasui, Y., Wollstein, A., Murawski, C. D., & Kennedy, J. G. (2017). Operative Treatment for Osteochondral Lesions of the Talus: Biologics and Scaffold-Based Therapy. Cartilage, 8(1), 42-49. https://doi.org/10.1177/1947603516644298
Yasui, Youichi, et al. "Operative Treatment for Osteochondral Lesions of the Talus: Biologics and Scaffold-Based Therapy." Cartilage vol. 8,1 (2017): 42-49. doi: https://doi.org/10.1177/1947603516644298
Yasui Y, Wollstein A, Murawski CD, Kennedy JG. Operative Treatment for Osteochondral Lesions of the Talus: Biologics and Scaffold-Based Therapy. Cartilage. 2017 Jan;8(1):42-49. doi: 10.1177/1947603516644298. Epub 2016 May 09. PMID: 27994719; PMCID: PMC5154422.
Copy Download .nbib Format: NLM
Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.

Case reports in gastroenterology

Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O.
PMID: 27721720
Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016.

Direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of hepatitis C virus (HCV) in liver transplant recipients. In this case study, we present a female with a graft reinfected with HCV genotype 2 who was...

Cite
Sasaki R, Kanda T, Ohtsuka M, et al. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016;10(2):366-372doi: 10.1159/000447423.
Sasaki, R., Kanda, T., Ohtsuka, M., Yasui, S., Haga, Y., Nakamura, M., Yokoyama, M., Wu, S., Nakamoto, S., Arai, M., Maruyama, H., Miyazaki, M., & Yokosuka, O. (2016). Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case reports in gastroenterology, 10(2), 366-372. https://doi.org/10.1159/000447423
Sasaki, Reina, et al. "Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin." Case reports in gastroenterology vol. 10,2 (2016): 366-372. doi: https://doi.org/10.1159/000447423
Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016. PMID: 27721720; PMCID: PMC5043295.
Copy Download .nbib Format: NLM
The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma.

Gastrointestinal tumors

Kobayashi S, Tomokuni A, Takahashi H, Akita H, Sugimura K, Miyoshi N, Moon JH, Yasui M, Omori T, Ohue M, Fujiwara Y, Yano M, Sakon M.
PMID: 28611981
Gastrointest Tumors. 2017 Mar;3(3):141-152. doi: 10.1159/000455955. Epub 2017 Feb 08.

BACKGROUND/AIMS: Alpha-fetoprotein (AFP) mRNA-expressing cells are candidates for circulating tumor cells in hepatocellular carcinoma. We analyzed portal vein blood, peripheral blood, and peritoneal lavage samples to detect the presence of AFP mRNA-expressing cells, and explored their relationship with metastasis.METHODS:...

Cite
Kobayashi S, Tomokuni A, Takahashi H, et al. The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma. Gastrointest Tumors. 2017;3(3):141-152doi: 10.1159/000455955.
Kobayashi, S., Tomokuni, A., Takahashi, H., Akita, H., Sugimura, K., Miyoshi, N., Moon, J. H., Yasui, M., Omori, T., Ohue, M., Fujiwara, Y., Yano, M., & Sakon, M. (2017). The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma. Gastrointestinal tumors, 3(3), 141-152. https://doi.org/10.1159/000455955
Kobayashi, Shogo, et al. "The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma." Gastrointestinal tumors vol. 3,3 (2017): 141-152. doi: https://doi.org/10.1159/000455955
Kobayashi S, Tomokuni A, Takahashi H, Akita H, Sugimura K, Miyoshi N, Moon JH, Yasui M, Omori T, Ohue M, Fujiwara Y, Yano M, Sakon M. The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma. Gastrointest Tumors. 2017 Mar;3(3):141-152. doi: 10.1159/000455955. Epub 2017 Feb 08. PMID: 28611981; PMCID: PMC5465674.
Copy Download .nbib Format: NLM
Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban.

Case reports in medicine

Nakasuka K, Ito S, Noda T, Hasuo T, Sekimoto S, Ohmori H, Inomata M, Yoshida T, Tamai N, Saeki T, Suzuki S, Murakami Y, Sato K.
PMID: 25477972
Case Rep Med. 2014;2014:814524. doi: 10.1155/2014/814524. Epub 2014 Nov 13.

A 42-year-old man was admitted to our hospital because of lumbago and tachycardia-induced heart failure. Transthoracic echocardiography revealed impaired left ventricular function and a ball mass of thrombus in the left ventricle (LV). He was found to have systemic...

Cite
Nakasuka K, Ito S, Noda T, et al. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep Med. 2014;2014:814524doi: 10.1155/2014/814524.
Nakasuka, K., Ito, S., Noda, T., Hasuo, T., Sekimoto, S., Ohmori, H., Inomata, M., Yoshida, T., Tamai, N., Saeki, T., Suzuki, S., Murakami, Y., & Sato, K. (2014). Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case reports in medicine, 2014814524. https://doi.org/10.1155/2014/814524
Nakasuka, Kosuke, et al. "Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban." Case reports in medicine vol. 2014 (2014): 814524. doi: https://doi.org/10.1155/2014/814524
Nakasuka K, Ito S, Noda T, Hasuo T, Sekimoto S, Ohmori H, Inomata M, Yoshida T, Tamai N, Saeki T, Suzuki S, Murakami Y, Sato K. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep Med. 2014;2014:814524. doi: 10.1155/2014/814524. Epub 2014 Nov 13. PMID: 25477972; PMCID: PMC4247908.
Copy Download .nbib Format: NLM
Data set for volumetric and pathological findings of epicardial adipose tissue.

Data in brief

Kitagawa T, Yamamoto H, Sentani K, Takahashi S, Tsushima H, Senoo A, Yasui W, Sueda T, Kihara Y.
PMID: 26568976
Data Brief. 2015 Sep 30;5:337-41. doi: 10.1016/j.dib.2015.09.016. eCollection 2015 Dec.

This article contains the data regarding clinically-assessed visceral adipose tissue (VAT) area and epicardial adipose tissue (EAT) volume on computed tomography (CT) images and EAT pathology, represented by inflammation and neoangiogenesis, complementing the data reported by Kitagawa et al....

Cite
Kitagawa T, Yamamoto H, Sentani K, et al. Data set for volumetric and pathological findings of epicardial adipose tissue. Data Brief. 2015;5:337-41doi: 10.1016/j.dib.2015.09.016.
Kitagawa, T., Yamamoto, H., Sentani, K., Takahashi, S., Tsushima, H., Senoo, A., Yasui, W., Sueda, T., & Kihara, Y. (2015). Data set for volumetric and pathological findings of epicardial adipose tissue. Data in brief, 5337-41. https://doi.org/10.1016/j.dib.2015.09.016
Kitagawa, Toshiro, et al. "Data set for volumetric and pathological findings of epicardial adipose tissue." Data in brief vol. 5 (2015): 337-41. doi: https://doi.org/10.1016/j.dib.2015.09.016
Kitagawa T, Yamamoto H, Sentani K, Takahashi S, Tsushima H, Senoo A, Yasui W, Sueda T, Kihara Y. Data set for volumetric and pathological findings of epicardial adipose tissue. Data Brief. 2015 Sep 30;5:337-41. doi: 10.1016/j.dib.2015.09.016. eCollection 2015 Dec. PMID: 26568976; PMCID: PMC4602350.
Copy Download .nbib Format: NLM
Seed/Catalyst-Free Growth of Gallium-Based Compound Materials on Graphene on Insulator by Electrochemical Deposition at Room Temperature.

Nanoscale research letters

Rashiddy Wong F, Ahmed Ali A, Yasui K, Hashim AM.
PMID: 26055478
Nanoscale Res Lett. 2015 Dec;10(1):943. doi: 10.1186/s11671-015-0943-y. Epub 2015 May 27.

We report the growth of gallium-based compounds, i.e., gallium oxynitride (GaON) and gallium oxide (Ga2O3) on multilayer graphene (MLG) on insulator using a mixture of ammonium nitrate (NH4NO3) and gallium nitrate (Ga(NO3)3) by electrochemical deposition (ECD) method at room...

Cite
Rashiddy Wong F, Ahmed Ali A, Yasui K, et al. Seed/Catalyst-Free Growth of Gallium-Based Compound Materials on Graphene on Insulator by Electrochemical Deposition at Room Temperature. Nanoscale Res Lett. 2015;10(1):943doi: 10.1186/s11671-015-0943-y.
Rashiddy Wong, F., Ahmed Ali, A., Yasui, K., & Hashim, A. M. (2015). Seed/Catalyst-Free Growth of Gallium-Based Compound Materials on Graphene on Insulator by Electrochemical Deposition at Room Temperature. Nanoscale research letters, 10(1), 943. https://doi.org/10.1186/s11671-015-0943-y
Rashiddy Wong, Freddawati, et al. "Seed/Catalyst-Free Growth of Gallium-Based Compound Materials on Graphene on Insulator by Electrochemical Deposition at Room Temperature." Nanoscale research letters vol. 10,1 (2015): 943. doi: https://doi.org/10.1186/s11671-015-0943-y
Rashiddy Wong F, Ahmed Ali A, Yasui K, Hashim AM. Seed/Catalyst-Free Growth of Gallium-Based Compound Materials on Graphene on Insulator by Electrochemical Deposition at Room Temperature. Nanoscale Res Lett. 2015 Dec;10(1):943. doi: 10.1186/s11671-015-0943-y. Epub 2015 May 27. PMID: 26055478; PMCID: PMC4451189.
Copy Download .nbib Format: NLM
Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.

Molecular and clinical oncology

Horie Y, Yamazaki K, Funakoshi T, Hamauchi S, Taniguchi H, Tsushima T, Todaka A, Machida N, Taku K, Fukutomi A, Onozawa Y, Yasui H, Mizukami T, Izawa N, Hirakawa M, Tsuda T, Nakajima T, Boku N.
PMID: 26623045
Mol Clin Oncol. 2015 Sep;3(5):1029-1034. doi: 10.3892/mco.2015.586. Epub 2015 Jun 24.

The efficacy of cetuximab correlates with the severity of skin toxicity, although its onset may vary. The AIM of this retrospective study was to investigate the optimal observation period for skin rash as a predictor of the efficacy of...

Cite
Horie Y, Yamazaki K, Funakoshi T, et al. Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin. Mol Clin Oncol. 2015;3(5):1029-1034doi: 10.3892/mco.2015.586.
Horie, Y., Yamazaki, K., Funakoshi, T., Hamauchi, S., Taniguchi, H., Tsushima, T., Todaka, A., Machida, N., Taku, K., Fukutomi, A., Onozawa, Y., Yasui, H., Mizukami, T., Izawa, N., Hirakawa, M., Tsuda, T., Nakajima, T., & Boku, N. (2015). Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin. Molecular and clinical oncology, 3(5), 1029-1034. https://doi.org/10.3892/mco.2015.586
Horie, Yoshiki, et al. "Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin." Molecular and clinical oncology vol. 3,5 (2015): 1029-1034. doi: https://doi.org/10.3892/mco.2015.586
Horie Y, Yamazaki K, Funakoshi T, Hamauchi S, Taniguchi H, Tsushima T, Todaka A, Machida N, Taku K, Fukutomi A, Onozawa Y, Yasui H, Mizukami T, Izawa N, Hirakawa M, Tsuda T, Nakajima T, Boku N. Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin. Mol Clin Oncol. 2015 Sep;3(5):1029-1034. doi: 10.3892/mco.2015.586. Epub 2015 Jun 24. PMID: 26623045; PMCID: PMC4534823.
Copy Download .nbib Format: NLM
Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.

World journal of hepatology

Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O.
PMID: 26052401
World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125.

Chronic hepatitis C virus (HCV) infection can cause liver cirrhosis and hepatocellular carcinoma (HCC). Several studies have demonstrated that the eradication of HCV reduces the occurrence of HCC. In Japan, as many people live to an advanced age, HCV-infected...

Cite
Sasaki R, Kanda T, Nakamoto S, et al. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015;7(8):1125-32doi: 10.4254/wjh.v7.i8.1125.
Sasaki, R., Kanda, T., Nakamoto, S., Haga, Y., Nakamura, M., Yasui, S., Jiang, X., Wu, S., Arai, M., & Yokosuka, O. (2015). Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World journal of hepatology, 7(8), 1125-32. https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki, Reina, et al. "Natural interferon-beta treatment for patients with chronic hepatitis C in Japan." World journal of hepatology vol. 7,8 (2015): 1125-32. doi: https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125. PMID: 26052401; PMCID: PMC4450189.
Copy Download .nbib Format: NLM
Synthesis of gallium nitride nanostructures by nitridation of electrochemically deposited gallium oxide on silicon substrate.

Nanoscale research letters

Ghazali NM, Yasui K, Hashim AM.
PMID: 25593562
Nanoscale Res Lett. 2014 Dec 18;9(1):685. doi: 10.1186/1556-276X-9-685. eCollection 2014.

Gallium nitride (GaN) nanostructures were successfully synthesized by the nitridation of the electrochemically deposited gallium oxide (Ga2O3) through the utilization of a so-called ammoniating process. Ga2O3 nanostructures were firstly deposited on Si substrate by a simple two-terminal electrochemical technique...

Cite
Ghazali NM, Yasui K, Hashim AM. Synthesis of gallium nitride nanostructures by nitridation of electrochemically deposited gallium oxide on silicon substrate. Nanoscale Res Lett. 2014;9(1):685doi: 10.1186/1556-276X-9-685.
Ghazali, N. M., Yasui, K., & Hashim, A. M. (2014). Synthesis of gallium nitride nanostructures by nitridation of electrochemically deposited gallium oxide on silicon substrate. Nanoscale research letters, 9(1), 685. https://doi.org/10.1186/1556-276X-9-685
Ghazali, Norizzawati Mohd, et al. "Synthesis of gallium nitride nanostructures by nitridation of electrochemically deposited gallium oxide on silicon substrate." Nanoscale research letters vol. 9,1 (2014): 685. doi: https://doi.org/10.1186/1556-276X-9-685
Ghazali NM, Yasui K, Hashim AM. Synthesis of gallium nitride nanostructures by nitridation of electrochemically deposited gallium oxide on silicon substrate. Nanoscale Res Lett. 2014 Dec 18;9(1):685. doi: 10.1186/1556-276X-9-685. eCollection 2014. PMID: 25593562; PMCID: PMC4273690.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1473 entries